New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
Subscribe To Our Newsletter & Stay Updated
